Daniel Velasco-Sanchez and Apostolos Tzikas contributed equally to this work.
Pediatric and Congenital Heart Disease
Transcatheter closure of perimembranous ventricular septal defects
Initial human experience with the Amplatzer® membranous VSD occluder 2
Article first published online: 15 MAY 2013
Copyright © 2013 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 82, Issue 3, pages 474–479, 1 September 2013
How to Cite
Velasco-Sanchez, D., Tzikas, A., Ibrahim, R. and Miró, J. (2013), Transcatheter closure of perimembranous ventricular septal defects. Cathet. Cardiovasc. Intervent., 82: 474–479. doi: 10.1002/ccd.24361
- Issue published online: 26 AUG 2013
- Article first published online: 15 MAY 2013
- Accepted manuscript online: 16 MAR 2012 10:43AM EST
- Manuscript Accepted: 2 FEB 2012
- Manuscript Revised: 21 DEC 2011
- Manuscript Received: 12 SEP 2011
- LaCaixa Foundation, Spain and the Sainte-Justine Hospital Foundation, Montreal, Canada, Hellenic Cardiology Foundation, The Hellenic Society of Cardiology
- perimembranous ventricular septal defect;
Although effective, transcatheter closure of perimembranous ventricular septal defects (pmVSD) with the Amplatzer Membranous VSD Occluder (AGA Medical Corporation, MN) carries a substantial risk of complete heart block, prompting many to abandon this intervention. A newly designed Amplatzer device for pmVSD was modified, in part, to minimize this risk. After rigorous preclinical testing, we report the first human experience with the Amplatzer Membranous VSD Occluder 2 (AGA Medical Corporation) in two patients (a 5-year old with a 12-mm pmVSD and a 26-year-old male with a 8-mm defect). Both procedures were successful, with no adverse events at 7 and 4 weeks of follow-up, respectively. Herein, we discuss characteristics of the new device, potential advantages compared to the prior version, and main technical aspects related to the procedure. © 2013 Wiley Periodicals, Inc.